Skip to content

The Diagnostic Accuracy of Subtractionless multi-point Dixon Peripheral MR Angiography The DOGMA TRIAL

The Diagnostic Accuracy of Subtractionless multi-point Dixon Peripheral MR Angiography The DOGMA TRIAL - The DOGMA TRIAL

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON41042
Enrollment
100
Registered
2015-10-14
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atherosclerosis peripheral arterial disease

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - 18 years or older - Suspected presence of peripheral arterial disease based on duplex ultrasonography, magnetic resonance angiography or CT angiography requiring percutaneous intervention - willing and able to give informed consent

Exclusion criteria

Exclusion criteria: - Presence of metal implants incompatible with safe MR imaging as determined from the recent copy of the *MR safety manual* by Shellock et al. - claustrophobia - presence of metal fragments in the orbit or eye - severe renal impairment (GFR

Design outcomes

Primary

MeasureTime frame
To determine the diagnostic accuracy (sensitivity, specificity, NPV and PPV) for the detection and the severity (%) of peripheral vascular tree stenosis with subtractionless first-pass single contrast medium dose peripheral MR angiography using two-point mDixon fat suppression compared to IA-DSA in patients with peripheral arterial disease referred for percutaneous intervention.

Secondary

MeasureTime frame
1. To compare the diagnostic accuracy of subtractionless first-pass single mDixon MRA with conventional subtraction MRA compared to the reference standard DSA in patients with peripheral arterial disease referred for percutaneous intervention in participating centers performing subtraction MRA in their clinical routine workup. 2. Does mDixon MRA lead to similar treatment decisions as IA-DSA determined by an expert consensus panel consisting of experienced cardiovascular radiologists and vascular surgeons 3. To compare the diagnostic accuracy of mDixon MRA on a station by station level (i.e. at the aorto-iliac, upper leg and lower leg levels).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)